Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil
Rev. Soc. Bras. Med. Trop
; 52: e20180272, 2019. tab, graf
Article
在 En
| LILACS
| ID: biblio-1041550
Responsible library:
BR1.1
ABSTRACT
Abstract INTRODUCTION:
Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil.METHODS:
A decision model estimated the life expectancy and costs of six diagnostic-therapeutic strategies.RESULTS:
IT LEISH + liposomal amphotericin B emerged the best option, presenting lower costs and higher effectiveness. DAT-LPC + liposomal amphotericin B showed an incremental cost-effectiveness ratio of US$ 326.31 per life year.CONCLUSIONS:
These findings indicate the feasibility of incorporating DAT and designating liposomal amphotericin B as the first-line drug for VL in Brazil.Key words
全文:
1
索引:
LILACS
主要主题:
Amphotericin B
/
Cost-Benefit Analysis
/
Leishmaniasis, Visceral
/
Meglumine
/
Antiprotozoal Agents
研究类型:
Diagnostic_studies
/
Health_economic_evaluation
/
Prognostic_studies
限制:
Humans
国家/地区名称主题:
America do sul
/
Brasil
语言:
En
期刊:
Rev. Soc. Bras. Med. Trop
期刊主题:
MEDICINA TROPICAL
年:
2019
类型:
Article